NCT00035087

EPO906 Therapy in Patients With Advanced Colorectal Cancer

An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Colorectal Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause colorectal cancer.

Conditions

• Colorectal Neoplasms
• Colonic Neoplasms

Interventions

Type	Name	Description
DRUG	epothilone b

Timeline

• Start date: 2002-05-01
• Primary completion: 2003-03-01
• Completion: 2003-03-01
• First posted: 2002-05-03
• Last updated: 2013-12-04

Locations

1 site across 1 country: United States